Alvotech (ALVO) Competitors $8.09 +0.06 (+0.68%) As of 02:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALVO vs. BBIO, ELAN, VRNA, ROIV, GRFS, RVMD, RYTM, LEGN, RGC, and RNAShould you be buying Alvotech stock or one of its competitors? The main competitors of Alvotech include BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Grifols (GRFS), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Regencell Bioscience (RGC), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. Alvotech vs. Its Competitors BridgeBio Pharma Elanco Animal Health Verona Pharma PLC American Depositary Share Roivant Sciences Grifols Revolution Medicines Rhythm Pharmaceuticals Legend Biotech Regencell Bioscience Avidity Biosciences Alvotech (NASDAQ:ALVO) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Do insiders and institutionals have more ownership in ALVO or BBIO? 99.9% of BridgeBio Pharma shares are owned by institutional investors. 0.5% of Alvotech shares are owned by insiders. Comparatively, 18.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is ALVO or BBIO more profitable? Alvotech has a net margin of 11.26% compared to BridgeBio Pharma's net margin of -329.25%. BridgeBio Pharma's return on equity of 0.00% beat Alvotech's return on equity.Company Net Margins Return on Equity Return on Assets Alvotech11.26% -38.36% 9.28% BridgeBio Pharma -329.25%N/A -85.69% Which has preferable earnings and valuation, ALVO or BBIO? Alvotech has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlvotech$491.98M4.95-$231.86M$0.2335.11BridgeBio Pharma$221.90M44.36-$535.76M-$4.09-12.59 Which has more volatility and risk, ALVO or BBIO? Alvotech has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Does the media favor ALVO or BBIO? In the previous week, BridgeBio Pharma had 12 more articles in the media than Alvotech. MarketBeat recorded 16 mentions for BridgeBio Pharma and 4 mentions for Alvotech. BridgeBio Pharma's average media sentiment score of 0.88 beat Alvotech's score of 0.68 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 8 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ALVO or BBIO? Alvotech presently has a consensus price target of $14.00, suggesting a potential upside of 73.37%. BridgeBio Pharma has a consensus price target of $61.35, suggesting a potential upside of 19.15%. Given Alvotech's higher possible upside, analysts clearly believe Alvotech is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alvotech 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryBridgeBio Pharma beats Alvotech on 9 of the 16 factors compared between the two stocks. Get Alvotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVO vs. The Competition Export to ExcelMetricAlvotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.43B$3.06B$5.75B$9.84BDividend YieldN/A2.26%3.95%4.02%P/E Ratio35.1121.2030.7626.60Price / Sales4.95383.15459.33120.41Price / CashN/A44.4437.7659.36Price / Book-14.178.1010.036.70Net Income-$231.86M-$54.08M$3.27B$265.68M7 Day Performance-4.66%2.77%3.36%3.42%1 Month Performance-17.69%3.89%4.58%1.09%1 Year Performance-30.69%18.96%44.38%23.94% Alvotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVOAlvotech2.0073 of 5 stars$8.09+0.7%$14.00+73.2%-31.5%$2.43B$491.98M35.111,032BBIOBridgeBio Pharma4.2232 of 5 stars$47.29-3.6%$61.35+29.7%+98.5%$9.38B$235.81M-11.56400ELANElanco Animal Health2.8598 of 5 stars$17.80-0.6%$17.33-2.6%+21.6%$8.90B$4.48B20.709,000VRNAVerona Pharma PLC American Depositary Share2.487 of 5 stars$105.62+0.1%$109.00+3.2%+289.3%$8.64B$221.67M-106.6930Positive NewsROIVRoivant Sciences3.1811 of 5 stars$11.64-2.3%$16.50+41.8%+1.2%$8.14B$29.05M-16.63860GRFSGrifols3.5948 of 5 stars$9.82-3.3%$10.30+4.9%+11.9%$6.99B$7.81B8.3923,822Positive NewsRVMDRevolution Medicines4.3218 of 5 stars$35.67-3.6%$69.92+96.0%-12.7%$6.92BN/A-7.93250News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.5242 of 5 stars$99.20-3.9%$101.57+2.4%+115.7%$6.86B$130.13M-32.96140Positive NewsInsider TradeLEGNLegend Biotech3.8986 of 5 stars$34.60-2.7%$73.00+111.0%-39.1%$6.53B$627.24M-39.322,609News CoveragePositive NewsAnalyst ForecastRGCRegencell Bioscience0.1441 of 5 stars$12.28-4.1%N/AN/A$6.33BN/A0.0010Gap UpRNAAvidity Biosciences2.9798 of 5 stars$45.27-2.3%$67.00+48.0%+9.4%$5.96B$10.90M-12.72190Positive News Related Companies and Tools Related Companies BBIO Competitors ELAN Competitors VRNA Competitors ROIV Competitors GRFS Competitors RVMD Competitors RYTM Competitors LEGN Competitors RGC Competitors RNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALVO) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alvotech Please log in to your account or sign up in order to add this asset to your watchlist. Share Alvotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access